Research programme: diketopiperazine compounds - Neuren Pharmaceuticals

Drug Profile

Research programme: diketopiperazine compounds - Neuren Pharmaceuticals

Alternative Names: NNZ-2591

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuren Pharmaceuticals
  • Class Cyclic peptides; Piperazines; Small molecules
  • Mechanism of Action Cell death inhibitors; Immunomodulators; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis; Neurological disorders; Parkinson's disease; Stroke

Most Recent Events

  • 05 Dec 2017 Neuren Pharmaceuticals receives patent allowance for NNZ 2591 in USA
  • 30 Nov 2015 Neuren has patent protection for NNZ 2591 in European Union and has an international patent pending for NNZ 2591
  • 11 Sep 2014 Preclinical development in Neurological disorders, Parkinson’s disease and Stroke, is now underway in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top